Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors,
Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH
Treatment Trial)
Research Question:
Does the drug erdafitinib treat patients with solid tumors, non-Hodgkin lymphoma or
histiocytic disorders?
Basic Study Information
Purpose:
This phase II Pediatric MATCH trial studies how well erdafitinib works in treating
patients
with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that have spread
to other
places in the body and have come back or do not respond to treatment with FGFR mutations.
Erdafitinib may stop the growth of cancer cells by blocking some of the enzymes needed
for
cell growth.
Location: University of Rochester
Lead Researcher (Principal Investigator)
Lead Researcher:
Angela Girvin
Study Contact Information
Study Coordinator: Site Public Contact
Phone: (585) 275-5830
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search